Raludotatug deruxtecan

Raludotatug deruxtecan
Identifiers
CAS Number
DrugBank
UNII
ChEMBL

Raludotatug deruxtecan (DS-6000) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that consists of a humanized IgG1 monoclonal antibody against the tumor-associated antigen cadherin-6 (CDH6), conjugated to deruxtecan (DXd), a cytotoxic DNA topoisomerase I inhibitor.[1]

References

  1. ^ Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, et al. (2024). "Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models". Molecular Cancer Therapeutics. 23 (3): 257–271. doi:10.1158/1535-7163.MCT-23-0287. PMC 10911705. PMID 38205802.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.